---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-26-034077"
form_type: "8-K"
ticker: "JUNS"
cik: "0001679628"
company_name: "JUPITER NEUROSCIENCES, INC."
filed_at: "2026-07-21T20:05:31+00:00"
generated_at: "2026-07-21T20:07:29.051143+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Jupiter Neurosciences signs exclusive US license for PharmAla's ALA-002 MDMA program

## Summary
- Upfront payment of $3.33M: $1.5M cash (net of $600K escrow) plus $1.83M in Jupiter common stock.
- Development milestones up to $23.33M: $3.33M on Phase 3 first dosing, $20M on first FDA NDA approval.
- Commercialization milestones up to $73.33M: $10M at $333M net sales, $30M at $1B, $33.33M at $2B.
- Royalty of 3% on net sales in the Territory, beginning after the third commercialization milestone is payable.
- Exclusive license for all human therapeutic uses in the US; Jupiter must use commercially reasonable efforts to develop and commercialize.

## SEC filing metadata
- accession: 0001493152-26-034077
- form_type: 8-K
- ticker: JUNS
- cik: 0001679628
- company_name: JUPITER NEUROSCIENCES, INC.
- filed_at: 2026-07-21T20:05:31+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 1.01, 3.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1679628/000149315226034077/0001493152-26-034077-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1679628/000149315226034077/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-26-034077
- JSON: https://secwatch.observer/filing/0001493152-26-034077.json
- Plain text: https://secwatch.observer/filing/0001493152-26-034077.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.